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Myopathy is a group of muscle diseases that can be induced or exacerbated by drug–drug interactions (DDIs). We sought to
identify clinically important myopathic DDIs and elucidate their underlying mechanisms. Five DDIs were found to increase
the risk of myopathy based on analysis of observational data from the Indiana Network of Patient Care. Loratadine
interacted with simvastatin (relative risk 95% confidence interval [CI]5 [1.39, 2.06]), alprazolam (1.50, 2.31), ropinirole
(2.06, 5.00), and omeprazole (1.15, 1.38). Promethazine interacted with tegaserod (1.94, 4.64). In vitro investigation
showed that these DDIs were unlikely to result from inhibition of drug metabolism by CYP450 enzymes or from inhibition of
hepatic uptake via the membrane transporter OATP1B1/1B3. However, we did observe in vitro synergistic myotoxicity of
simvastatin and desloratadine, suggesting a role in loratadine–simvastatin interaction. This interaction was
epidemiologically confirmed (odds ratio 95% CI5 [2.02, 3.65]) using the data from the US Food and Drug Administration
Adverse Event Reporting System.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Drug-induced myopathy can be exacerbated by DDIs.
No study to date has attempted to identify and investigate myopathic DDIs systematically.  WHAT QUESTION DID
THIS STUDY ADDRESS?  This study identified DDIs that increased risk of myopathy and investigated their underlying
mechanisms using a high-throughput, translational approach.  WHAT THIS STUDY ADDS TO OUR KNOWLEDGE 
Five previously unknown DDIs were identified to increase the risk of myopathy, none of which appeared to result from
inhibition of drug metabolism or hepatic uptake via OATP1B1/1B3. Synergistic myotoxicity may contribute to the interac-
tion between loratadine and simvastatin.  HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THER-
APEUTICS  Pharmacoepidemiologic screening followed by mechanistic investigations proved to be an efficient approach
to identify clinically important DDIs.
Drug-induced myopathy, among the most common causes of
muscle disease,1 has clinical presentations ranging from asymp-
tomatic muscle enzyme elevation to massive rhabdomyolysis with
acute renal failure.2 Among 7 million case reports in the US
Food and Drug Administration (FDA) Adverse Event Reporting
System (FAERS) from 2001–2010, about 100,000 cases involved
myopathy as a suspected adverse drug reaction (ADR).3 Among
various drug classes associated with myopathy, statins have
received extensive public and scientiﬁc attention. Statin-induced
myopathy occurs in 5–20% of patients and is a signiﬁcant barrier
to maximizing the beneﬁts of statin therapy.4 Considering that
more than 18% of Americans aged 45 (127 million) took sta-
tins in 2012, 1.1 to 4.6 million patients might have experienced
myopathy in 2012 alone.
Drug-induced myopathy can be exacerbated by pharmacoki-
netic and/or pharmacodynamic drug–drug interactions (DDIs).
In a pharmacokinetic myopathic DDI, the object drug induces
myopathy, and the precipitant drug modiﬁes the object drug’s
myopathic effects by changing its pharmacokinetics. One such
example is the interaction between cerivastatin and gemﬁbrozil
that contributed to the withdrawal of cerivastatin from the mar-
ket.5 The risk of cerivastatin-induced rhabdomyolysis is 10-fold
higher than that of other statins; with concurrent use of gemﬁ-
brozil, a drug that substantially inhibits the metabolism of ceri-
vastatin, the risk is 50-fold higher.6
Although drug-induced myopathy and the role of DDIs as risk
factors have been well documented, to our knowledge no study
has attempted to identify and investigate unknown myopathic
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DDIs systematically. Research on DDIs has been mostly limited
to pharmacokinetic DDIs with identiﬁable mechanisms, a small
scope, a relatively low efﬁciency, and often a low clinical rele-
vance. Recognizing the need for a translational approach for the
study of DDIs,7 a promising new strategy involves pairing epide-
miological studies with mechanistic investigations such as in vitro
screening for metabolism-based DDIs. This approach was
recently successfully applied to the study of interactions between
sulfonylureas and statins/ﬁbrates.8 Our previous study predicted
13,197 potentially interacting drug pairs using data mined from
PubMed abstracts,9 and narrowed down to 3,670 clinically pre-
scribed drug pairs using data derived from electronic medical
records.9 In the current study, by applying a large-scale, transla-
tional approach, we sought to identify interacting drug pairs asso-
ciated with myopathy and to elucidate their underlying
pharmacokinetic and pharmacodynamic mechanisms.
RESULTS
DDIs associated with increased risk of myopathy
We applied the myopathy concept deﬁnition (Supplementary
Table S1) to a subset (n5 828,905) of the Indiana Network for
Patient Care (INPC) database (2004–2009) formatted in the
Observational Medical Outcomes Partnership10 Common Data
Model. We identiﬁed 59,572 myopathy cases, of which 48,877
(5.9%) had myalgia and myositis, 12,720 (1.5%) had muscle
weakness, and 53 (0.0064%) had rhabdomyolysis. For each of the
3,670 drug pairs that we previously predicted to interact,9 we per-
formed a simple cohort study. The demographics of the patient
population were described previously9 and are shown in Supple-
mentary Table S2. Since race information was missing for
65.8% of the patients, it was not included in the analyses. For
each drug pair, we estimated a risk ratio (RR) adjusted for age
and sex, both known risk factors of myopathy.11 An RR greater
than 1 indicated that the incidence of myopathy following the
prescriptions for both drugs was greater than the additive inci-
dence following a prescription for either drug alone. Drug pairs
with RRs greater than 1 were therefore considered to be interact-
ing and associated with an increased risk of myopathy. As a small
sample size may yield an unreliable estimate of risk ratio, drug
pairs with counts of myopathy cases less than 100 were excluded.
We identiﬁed ﬁve DDIs associated with an increased risk of
myopathy (Table 1), four of which involved the widely used anti-
histamine loratadine. The risk of myopathy increased with age at
1.0015 (95% conﬁdence interval [CI]5 1.00148, 1.00152) per
year, and was 1.64-fold (95% CI5 1.63, 1.65) higher in females
(8.6%) than in males (5.4%) (Supplementary Table S3). Since
sicker patients tend to take more medications, we used the num-
ber of prescribed medications, including the relevant drug pair,
within drug exposure windows to adjust for confounding by mor-
bidity. The average number of prescribed medications was
3.86 2.5. The ﬁve DDIs remained signiﬁcant after adjusting for
the number of coprescribed medications (Supplementary
Table S4).
Inhibition of CYP-mediated drug metabolism
Cytochrome P450s (CYPs) are responsible for about 75% of
drug metabolism,12 and their inhibition is a common mechanism
of pharmacokinetic DDIs.12 Since each drug in the ﬁve DDIs
relies on CYPs for elimination, we examined whether the DDIs
were possibly caused by inhibition of CYP drug metabolism.
Using ﬂuorometric CYP inhibition screening assays, we assessed
the potential of the drugs, and their pharmacologically active
metabolites, to inhibit the enzymatic activities of the major
human CYPs isoforms CYP1A2, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, and CYP3A4. The half maximal inhibi-
tory concentration (IC50s) are presented in Supplementary
Table S6. It is commonly accepted that a dissociation constant
(Ki) is more relevant than an IC50 when predicting the clinical
risk of metabolism-based DDIs. We therefore determined Kis for
11 drug-enzyme pairs (Table 2) that showed relatively strong
CYP inhibitions (IC50 20 lM).
Following FDA guidelines for drug interaction studies,13 we
applied a stepwise approach to evaluate the risk of clinical DDIs
resulting from inhibition of drug metabolism by CYPs. For each
of the 11 drug-enzyme pairs for which a Ki was observed, we ﬁrst
used a conservative R-value approach to evaluate each drug’s
potential to act as a hypothetical precipitant. An R-value repre-
sents the predicted ratio of the area under concentration–time
curve (AUC) of a hypothetical object drug that is exclusively
metabolized by the inhibited CYP in the presence vs. absence of
an inhibitor. Table 2 shows the predicted R-values. Consistent
with FDA guidelines,13 an R value 1.1 (or 11 for CYP3A4
inhibitors administered orally) indicates that the drug could act
as a precipitant. With R-values of 1.31 and 1.15, respectively,
Table 1 Drug–drug interactions associated with increased risk of myopathy after adjusting for age and sex
Drug 1 Drug 2 Risk1 Risk2 Risk12 Risk ratio (95% CI) M1 N1 M2 N2 M12 N12
Loratadine Simvastatin 0.022 0.033 0.093 1.69 (1.39, 2.06) 1,264 44,245 4,197 102,345 137 1,223
Loratadine Alprazolam 0.022 0.029 0.095 1.86 (1.50, 2.31) 1,257 43,341 2,251 52,341 176 1,448
Loratadine Ropinirole 0.020 0.018 0.122 3.21 (2.06, 5.00) 1,218 43,491 164 6,531 17 123
Promethazine Tegaserod 0.011 0.020 0.093 3.00 (1.94, 4.64) 1,332 78,334 109 3,745 23 224
Loratadine Omeprazole 0.022 0.059 0.102 1.26 (1.15, 1.38) 1,260 44,207 4,339 70,345 304 2,734
Risk1 and risk2 are myopathy risks for drug 1 and drug 2, respectively. The risk ratios were calculated as risk12/(risk11risk2). 95% CIs were calculated using multivariate
logistic regression adjusted for age and sex. N1, N2, and N12 is the number of patients who had prescription for drug 1 only, drug 2 only, and both drugs, respectively; and
M1, M2, and M3 is the number of myopathy cases who had prescription for drug 1 only, drug 2 only, and both drugs, respectively.
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promethazine and ropinirole could potentially interact with
drugs exclusively metabolized by CYP2D6, the isoform most
strongly inhibited by both drugs. The predicted potential of the
other inhibitor-enzyme pairs was negligible. These determina-
tions suggest that the DDIs not involving promethazine and
ropinirole were unlikely to result from inhibition of drug metab-
olism by CYPs.
A limitation of R values is that they only account for inhibi-
tion of a single metabolic pathway without regard to object
drugs.14 In cases where multiple pathways are responsible for the
metabolism of an object drug, an AUC ratio (AUCR) taking
into account the fractional contribution of inhibited pathways to
the overall metabolism is preferred. We thus predicted AUCRs
for the interaction between ropinirole and loratadine, and that
between promethazine and tegaserod. Accounting for 10% of the
hepatic metabolism of loratadine by CYP2D6 that would be
inhibited by ropinirole,15 the AUCR of loratadine in the pres-
ence vs. absence of ropinirole was predicted to be 1.01. Consist-
ent with the FDA guidelines,13 it indicates that loratadine and
ropinirole are unlikely to have CYP-based interactions. Because
CYP2D6 is insigniﬁcant in tegaserod’s elimination,16 the inhibi-
tion of CYP2D6 by promethazine was considered to have no
clinical effect on the pharmacokinetics of tegaserod. Overall, our
data suggest that CYP inhibition is unlikely the major mecha-
nism underlying the signiﬁcant DDIs identiﬁed previously.
Inhibition of OATP1B1/1B3-mediated hepatic uptake
It has been increasingly recognized that organic anion-
transporting polypeptides (OATPs) represent an important site
of DDIs. Particular attention has been paid to OATP1B1 and
1B3, the transporters of the OATP family demonstrated as most
engaged in drug disposition.17 Among their substrates are many
clinically important drugs including simvastatin acid,18 the active
metabolite of simvastatin. The risk of simvastatin-induced myop-
athy was 4.5-fold higher in individuals with a genetic variant of
SLCO1B1 (the OATP1B1 gene), compared to those with the
wildtype allele.19
We hypothesized that the DDIs identiﬁed previously may
result from, at least in part, the inhibition of OATP1B1/1B3
that leads to impaired hepatic uptake and compromised hepatic
clearance. We ﬁrst evaluated the potential of the drugs, as well as
their pharmacologically active metabolites, to inhibit the active
uptake of b-estradiol 17-b-D-glucuronide (E217bDG) in cryo-
preserved rat hepatocytes. E217bDG is a relatively speciﬁc sub-
strate of OATP1B2, a functional homolog of human
OATP1B1/1B3 with very similar substrate speciﬁcity.17,20 At
100 lM, simvastatin acid, omeprazole, alprazolam, desloratadine
(the active metabolite of loratadine), simvastatin, tegaserod, ropi-
nirole, loratadine, and promethazine inhibited E217bDG uptake
by 103.36 0.5%, 60.16 4.8%, 54.56 0.3%, 44.96 14.2%,
36.36 6.0%, 24.66 15.3%, 23.76 2.7%, 18.16 10.9%, and
17.76 7.7%, respectively. We then determined the inhibitory
potencies of the drugs showing 45% inhibition. The IC50s
(95% CI) of simvastatin acid, omeprazole, alprazolam, and
desloratadine were 4.3 lM (3.5, 5.3), 84.3 lM (49.8, 142.9), 99.5
lM (79.5, 124.6), and 140.5 (111.4, 177.1) lM, respectively
(inhibition curves are shown in Supplementary Figure 1).
Following a similar strategy for evaluating CYP-based DDIs,
we estimated R-values (from IC50s) to evaluate the drugs’ poten-
tial to interact clinically with OATP1B1/1B3 substrates. The
R-values of simvastatin acid, omeprazole, alprazolam, and
desloratadine were 3.85, 1.23, 1.01, and 1.01, respectively
Table 2 Predicting potential of CYP-based drug–drug interaction
Inhibitor Pathway
Dissociation
constant
(Ki, mM)
Fraction
of unbound
(fu,inc)
Unbound
dissociation constant
(Ki,u, mM)
Peak plasma
concentration
(Cmax, ng/ml)
Inhibitor
concentration
([I], mM)
Predicted
R-values
Simvastatin CYP3A4 0.51 0.93 0.47 — 0.764 2.61
Promethazine CYP2D6 0.25 0.88 0.22 19.3 (36) 0.068 1.31*
Tegaserod CYP3A4 5 0.92 4.61 — 0.796 1.17
Ropinirole CYP2D6 0.85 0.84 0.71 26.9 (37) 0.103 1.15*
Loratadine CYP2D6 0.5 0.93 0.47 4.12 (38) 0.011 1.02
Tegaserod CYP2D6 0.51 0.92 0.47 2.7 (39) 0.009 1.02
Loratadine CYP2B6 2 0.93 1.86 4.12 (38) 0.011 1.01
Simvastatin CYP2C9 18.3 0.93 17.03 25.4 (40) 0.061 1.00
Loratadine CYP2C9 7.6 0.93 7.07 4.12 (38) 0.011 1.00
Tegaserod CYP2C19 9.2 0.92 8.48 2.7 (39) 0.009 1.00
Tegaserod CYP2C9 11.4 0.92 10.51 2.7 (39) 0.009 1.00
Ki is the dissociation constant determined in vitro; fu,inc is the fraction of unbound drug in the incubation mixture and was predicted using the Hallifax-Houston model
41; Ki,u
is the unbound dissociation constant estimated as Ki * fu,inc; Cmax is the peak total plasma concentration at the highest clinical dose; [I] is the inhibitor concentration used
to predict R values and is equal to Cmax, except for CYP3A4 inhibitors administered orally. For simvastatin and tegaserod with CYP3A4, [I] is the estimated gut concentra-
tion at the highest proposed clinical dose, 80 mg (191 mM) and 6 mg (19.9 mM), respectively, divided by 250 mL (approximate gut volume); R values were estimated as
11 [I]/Ki,inc; *R values 1.1 (or 11 for simvastatin and tegaserod with CYP3A4), indicating a probable clinical CYP450-based DDI.
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(Table 3). Consistent with the FDA guidelines,13 simvastatin
acid and omeprazole (R value 1.1) might interact with drugs
relying on OATP1B1/1B3 for hepatic uptake. The potential of
alprazolam and desloratadine as precipitants was negligible.
Direct myotoxicity
Although all the drugs involved in the DDIs have known muscle-
related side effects, their direct myotoxicity, except that of simva-
statin, has not been examined. We tested whether the DDIs
resulted from the direct toxicity of the individual drugs, or their
combinations, to muscle cells. We ﬁrst evaluated the myotoxicity
of each individual drug to rat L6 myotubes, a commonly used in
vitro skeletal muscle model previously used to study mechanisms
of statin-induced myopathy.21,22 After treatment of healthy, fully
differentiated myotubes with each drug individually at 10 lM for
5 days, tegaserod, simvastatin, desloratadine, and simvastatin acid
induced 97.96 0.4%, 73.76 2.6%, 73.36 1.1%, and
33.06 2.1% myotube death, respectively, compared to dimethyl
Figure 1 (a) Dose–response curves of simvastatin (orange), tegaserod (blue), and desloratadine (pink). Healthy, fully differentiated rat L6 myotubes
were treated with individual drugs at various concentrations for 5 days, and myotube viability was determined using MTS/PMS assays. (b) Concentration–
effect curves of simvastatin in the presence of various fixed concentrations of desloratadine at various concentrations. (d) Concentration–effect curves of
desloratadine in the presence of various fixed concentrations of simvastatin. (c) Combination index (CI) – fractional myotube death (fa) plot. CI51 indi-
cates additivity (no interaction). The points above 1 indicate antagonism and those below indicate synergism. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Table 3 Predicting potential of OATP1B1-based drug–drug interaction
Drug
Half maximum
inhibition concentration
(IC50, lM)
Dose
(mg/mmol)
Molecular
weight
(g/mol)
Peak plasma
concentration
(Cmax, lM)
Maximal hepatic inlet
concentration
([I]inlet,max, lM)
Predicted
R value
Simvastatin Acid 4.3 80/0.183 436.6 0.058 (40) 12.274 3.85
Omeprazole 84.3 80/0.232 345.42 4.146 (42) 19.586 1.23
Alprazolam 99.5 3/0.01 308.76 0.333 (43) 0.981 1.01
Desloratadine 140.5 5/0.16 310.8 0.015 (44) 1.088 1.01
Dose is the highest proposed clinical dose; Cmax is the peak plasma concentration at the highest proposed clinical dose; [I]inlet,max was estimated as Cmax1 (ka x Dose x
FaFg/Qh) (13), where Qh is the hepatic blood flow (1,500 mL/min), ka is the absorption rate constant, and FaFg is the fraction of oral dose that reaches the liver. Because
the values of ka and FaFg were not available, for conservative predictions, they were assumed equal to the theoretical maxima of 0.1 min
21 and 1,13 respectively. R values
were estimated as 11 [I]inlet,max/Ki. Because the concentration of E217bDG (1 lM) was well below its Km,
45,46 the Kis were approximated by the IC50s based on Ki5 IC50
/ (11 [S]/Km).
47 For simvastatin acid, the Cmax and dose were assumed equal to those of simvastatin. For desloratadine, R values were estimated with the Cmax following
the highest clinical dose of desloratadine since it is higher than the Cmax following that of loratadine.
48,49
ARTICLES
324 VOLUME 98 NUMBER 3 | SEPTEMBER 2015 | www.wileyonlinelibrary/cpt
sulfoxide (DMSO) control. The remaining drugs were not myo-
toxic. We then determined the concentration–effect curves of
tegaserod, simvastatin, and desloratadine since they induced
>50% myotube death. The IC50s (95% CI) of tegaserod, simvasta-
tin, and desloratadine were 4.32 lM (4.15, 4.49), 1.64 lM (1.05,
2.56), and 10.94 lM (9.24, 12.96), respectively (Figure 1a).
The myotoxicity of simvastatin and desloratadine led us to sus-
pect a synergistic interaction that increases risk of myotoxicity when
used in combination. We treated myotubes with simvastatin and
desloratadine in combination at various concentrations to evaluate
their combined toxic effect. The dose–response curves of simvastatin
shifted leftward with increasing concentration of desloratadine
(Figure 1b). The same trend was observed for desloratadine in the
presence of simvastatin (Figure 1d). Using the method of Chou,23
combination index (CI) values were calculated and plotted against
fractional myotube death (fa) (Figure 1c). Most CI values were less
than unity; a few CI values greater than unity near the region fa5 0
likely resulted from methodological ﬂaw,24 indicating that the inter-
action between simvastatin and desloratadine was synergistic, such
that the drugs notably increased each other’s myotoxic effect. This
synergistic myotoxicity may contribute to the interaction between
simvastatin and loratadine. Direct toxicity to muscle cells, however,
was unlikely to explain the other DDIs we identiﬁed.
Validation of loratadine-simvastatin interaction
The interaction between loratadine and simvastatin was further
validated using an independent dataset, the FAERS. A distinct fea-
ture of the FAERS is that it only includes patients who experience
suspected ADRs. As a case-only design was considered more appro-
priate using the FARES, we performed a similar study using the
INPC dataset to compare the results. An odds ratio (OR), esti-
mated from a case-only study, is equivalent to a relative risk esti-
mated from a cohort study.25 The ORs are presented in Table 4.
Consistent with the RRs presented previously, the concomitant
use of loratadine and simvastatin was signiﬁcantly associated with
increased risk of myopathy, with ORs of 2.20 (95% CI5 2.02,
3.65) and 1.53 (95% CI5 1.28, 1.82) in the FAERS and INPC
databases, respectively. In additional subgroup analyses stratiﬁed by
sex, age, or myopathy type (muscle weakness or myalgia), the inter-
action between loratadine and simvastatin remained signiﬁcant in
speciﬁc subgroups of patients (Supplementary Table S8).
DISCUSSION
Research on pharmacokinetic DDIs traditionally involves predic-
tion of potential DDIs based on molecular mechanistic under-
standing of the interaction between a drug and its relevant drug-
metabolizing enzymes or drug transporters. The clinical impor-
tance of hypothesized DDIs is then examined in clinical trials or
pharmacoepidemiologic studies. This approach is often limited to
a small scope and a relatively low efﬁciency when used to identify
unknown, clinically important DDIs. We sought to overcome
these limitations by applying a translational and systematic
approach involving pharmacoepidemiologic screening followed
by mechanistic investigations.
Our study identiﬁed a synergistic myotoxic interaction
between simvastatin and loratadine that has never been reported.
As simvastatin is one of the most widely prescribed statins, this
myopathic interaction could potentially affect a large population.
We suggest further studies to conﬁrm this interaction and its
myopathic effects. Simvastatin is known to interact clinically
with a number of drugs that may further increase its risk of
myopathy, including CYP3A inhibitors, such as verapamil, keto-
conazole, itraconazole, tacrolimus, erythromycin, clarithromycin,
and amiodarone26,27 and OATP1B1 inhibitors (e.g., gemﬁbro-
zil).28 Our study, however, did not identify any known DDIs
with statins that would increase the risk of myopathy, except for
amiodarone (Supplementary Table S5). One possible explana-
tion is that our predeﬁned 1-month drug exposure window can-
not well capture the concomitance of statins with many CYP3A
inhibitors that typically have short exposure. Amiodarone, how-
ever, is used chronically and its concomitance with statins is eas-
ier to capture. The other explanation is the underpowered
interaction analyses between statins and CYP3A inhibitors.
Power analysis for these reported DDIs in Supplementary
Table S5 showed that almost all of them had less than 10%
power, except for the interactions between amiodarone and statins,
which had power higher than 70%. Referring back to our initial
drug interaction study design, a requested minimum sample size of
100 for two-committed drugs and a minimum of 1.5 risk ratio
would give us 65% power in testing the drug interaction effect.
Four out of ﬁve DDIs identiﬁed in our study involved a com-
monly used antihistamine, loratadine. Myalgia is one of the side
effects of both loratadine and desloratadine.29,30 Our results sug-
gest that loratadine and desloratadine may be more myotoxic
than previously recognized, and can pose even higher risk of
myopathy with concomitant use of other drugs.
The IC50s and Kis that we reported provide a comprehensive
view of the potential of these drugs to cause CYP-based DDIs.
These data are consistent with those published previously.9 To
our knowledge, we are the ﬁrst to describe the potential of these
drugs (except simvastatin) to inhibit OATP1B2 in rat hepato-
cytes and assess their potential OATP-mediated DDIs in
humans. We are also likely the ﬁrst to report myotoxicity of
desloratadine and tegaserod, which may underlie their muscle-
Table 4 Testing and validation of the loratadine/simvastatin interaction using case-only datasets
Datasets Odds ratio 95% CI N12 N1 N2 N00
INPC CDM 1.53 (1.28, 1.82) 37 1,264 4,197 5,572
FAERS 2.20 (2.02, 3.65) 37 276 6,116 100,531
N12, N1, N2, and N00 is the number of myopathy cases with prescription for both simvastatin and loratadine, simvastatin only, loratadine only, and neither drug, respec-
tively. INPC CDM stands for Indiana Network of Patient Care Common Data Model. FAERS stands for the FDA adverse event reporting system.
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related side effects. Of note, simvastatin was much more toxic
than simvastatin acid to myotubes in vitro, an observation previ-
ously reported,31 suggesting that simvastatin-induced myopathy is
due primarily to simvastatin rather than simvastatin acid. Simi-
larly, the in vitro myotoxicity of desloratadine suggests that myal-
gia associated with loratadine may be primarily due to its
metabolite, desloratadine.
Although inhibition of drug metabolism by CYPs and inhibi-
tion of OATP1B1/1b3 are the most common mechanisms
underlying pharmacokinetic DDIs, they are unlikely the major
mechanisms for the DDIs that we observed. The results from the
R-value approach suggest that simvastatin acid and omeprazole
may interact with drugs that rely on OATP1B1/1B3 for hepatic
uptake. We suggest that such data be interpreted with caution, as
the R-value approach, for both CYPs and transporters, is known
to overpredict the risk of clinical DDIs and lead to spurious con-
clusions that a drug is a precipitant when it is not.32 It implies,
however, that the drug pairs predicted not to interact using this
approach in our study are very unlikely to have real interactions.
There are a few limitations to our study. We used a simple cohort
design that may be subject to residual confounding and misclassiﬁca-
tion. The use of the FAERS may not provide a deﬁnitive validation
for a simvastatin–loratadine interaction. The CYP450 inhibition
assays involve ﬂuorogenic substrates and recombinant CYP enzymes
that occasionally generate inhibitory potencies very different from
those using conventional approaches. Both the R value and AUCR
approaches use a single static in vivo concentration of an inhibitor
drug, which may overestimate the risk of DDI for drugs, such as
simvastatin, with relatively short half-lives and whose circulating
concentrations drop rapidly following a dose. We did not evaluate
the drugs as direct substrates of OATP1B1/1B3 or other transport-
ers, limiting our understanding of the role of drug transporters in
the DDIs. We also used cryopreserved rat hepatocytes and rat L6
myotubes, which are less clinically relevant than human-derived cell
models. Future studies are warranted to further evaluate the underly-
ing mechanisms of these DDIs.
METHODS
Evaluation of CYP450 inhibition
Fluorometric cytochrome P450 inhibition kits (BD Biosciences/Gentest,
San Jose, CA) were used to determine the IC50s of the drugs for the
major CYPs. The assays were performed following the manufacturer’s
instructions under the conditions in Supplementary Table S7.33 Data
were analyzed using GraphPad Prism 5 software (La Jolla, CA).
R values were estimated as 11 [I]/Ki,u, where [I] is the peak total
plasma inhibitor concentration (Cmax) at the highest proposed clinical
dose obtained from the published literature, and Ki,u is the unbound dis-
sociation constant of the inhibitor. For drugs that inhibited CYP3A4
administered orally, [I] was estimated as [I]5 Igut5molar dose/250 mL.
AUCRs were predicted using the mechanistic static model in Eq. 1,34
AUCR5AUCinhibitedAUC5FinhibitedF1jnfm;CYPj1
1½I Ki; unbound; j1ð12jnfm;CYpjÞ (1)
where fm,CYPj is the fractional metabolism of the object drug through the
jth inhibited CYP pathway, Finhibited and F are the bioavailabilities of
the object drug in the presence and absence of the inhibitor, respectively.
Because Finhibited and F were not available, for conservative prediction
they were assumed to be unity.
Evaluation of inhibition of OATP1B1/1B3
The drugs (100 lM) were incubated with cryopreserved rat hepatocytes
(1 3 106 cells/mL) and [3H] E217bDG (1 lM, 0.1 lCi) for 3 minutes
at 378C and 08C in triplicate. Uptake was stopped with addition of
1 mL ice-cold PBS and immediate centrifugation at 4500 rpm for 1
minute at 48C. Cells were resuspended in 1 mL ice-cold PBS and centri-
fuged again. After removing supernatant, cell pellets were lysed with
200 lL of 50% acetonitrile in H2O, followed by vigorous vortexing. The
fraction of uptake was the ratio of the radioactivity in hepatocyte lysate
to the total radioactivity in both lysate and supernatants. The fraction of
active uptake was the difference between the total uptake at 378C and
that at 08C.
Evaluation of myotoxicity
Rat L6 muscle cells were cultured as previously detailed by Klip and col-
leagues35 with slight modiﬁcations. Cells were maintained in monolayer
culture in a-MEM containing 10% fetal bovine serum (FBS) and 1%
antibiotic–antimycotic solution (10,000 U/ml penicillin G, 10 mg/ml
streptomycin, and 25 mg/ml amphotericin B) in an atmosphere of 5%
CO2 at 378C. Five days after seeding, myoblasts were differentiated into
multinucleated myotubes with 2% FBS. All drug treatments were initi-
ated 5 days after the initiation of differentiation and continued for 5
days. The CellTiter 96 aqueous nonradioactive cell proliferation (MTS/
PMS) assay (Promega, Madison, WI) was used to measure cell viability
after drug treatment.
Combination index (CI) values were calculated as described by
Chou.23 The fraction of unaffected (fu), in this case equivalent to cell
viability, was calculated as described above. Fractional inhibition (fa) was
calculated as 1 – fu. The slope factor m and IC50 of simvastatin and
desloratadine were estimated by ﬁtting the data of each drug when
applied alone to Eq. 2,
log fafu5m3logD2m3log ðDmÞ (2)
CI values were then calculated using Eq. 3,
CI5D1=ðD11D2ÞDm1ðfafuÞ1=m1
1D2=ðD11D2ÞDm2ðfafuÞ1=m2 (3)
A CI - fa plot was constructed by plotting CI values and fa on y and x
axes, respectively.
Additional Supporting Information may be found in the online version of
this article.
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